BioLife Solutions, Inc. Most Important Performance Measures
The measures each proxy statement lists as most important for linking pay to performance (Item 402(v) tabular list), as tagged, newest proxy first.
- 2023-06-06: Measure Revenue.
- 2023-06-06: Measure Adjusted Gross Margin (Non-GAAP).
- 2023-06-06: Measure Adjusted EBITDA (Non-GAAP).
- 2024-06-05: Measure Revenue.
| Proxy filed | Measure |
|---|
| 2023-06-06 | Revenue |
|---|
| 2023-06-06 | Adjusted Gross Margin (Non-GAAP) |
|---|
| 2023-06-06 | Adjusted EBITDA (Non-GAAP) |
|---|
| 2024-06-05 | Revenue |
|---|
| 2024-06-05 | Adjusted Gross Margin (Non-GAAP)(1) |
|---|
| 2024-06-05 | Adjusted EBITDA (Non-GAAP)(1)4.Total Shareholder Return(1) Adjusted Gross Margin and Adjusted EBITDA are non-GAAP metrics. For a reconciliation of these metrics to the most directly comparable GAAP measures, see the "Non-GAAP metric reconciliation tables" outlined within the Summary of 2023 performance measure and goals section of this proxy statement. |
|---|
| 2025-07-08 | Revenue |
|---|
| 2025-07-08 | Adjusted EBITDA (Non-GAAP)(1) |
|---|
| 2025-07-08 | Total Shareholder Return |
|---|